oritavancin (Novocid)
Jump to navigation
Jump to search
Indications
Dosage
Antimicrobial activity
- Staphylococcus aureus including MRSA
- Streptococcus
Adverse effects
- nausea, headache, diarrhea
- elevations of serum transaminases
- red man syndrome
Mechanism of action
- inhibition of bacterial cell wall formation (by analogy to dalbavancin)
Notes
More general terms
References
- ↑ Corey GR et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014 Jun 5; 370:2180. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24897083 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1310422
- ↑ 2.0 2.1 FDA News Release. August 6, 2014 FDA approves Orbactiv to treat skin infections http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm408475.htm
- ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16129632
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16136912
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16131319
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=44151739
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=70691404
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53297457